Phase II Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma
Latest Information Update: 10 Apr 2025
At a glance
- Drugs Mogamulizumab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisolone; Vincristine
- Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma; T-cell prolymphocytic leukaemia
- Focus Therapeutic Use
Most Recent Events
- 19 Dec 2024 Status changed from not yet recruiting to recruiting.
- 14 Oct 2024 Planned End Date changed from 1 Aug 2027 to 1 Nov 2027.
- 14 Oct 2024 Planned primary completion date changed from 1 Aug 2026 to 1 Nov 2026.